How can i apply for keytruda patient assistance programs?

How do I qualify for Keytruda patient assistance?
Merck’s patient assistance program (PAP) covers Keytruda at no cost for eligible uninsured or underinsured U.S. residents. You must have a prescription from a licensed U.S. healthcare provider, show household income at or below 400% of the federal poverty level, and lack adequate insurance coverage for the drug. The program does not cover patients with government insurance such as Medicare or Medicaid.

Where do I start the application?
Download the enrollment form from Merck’s site or request one by calling 855-257-2463. Your doctor must complete the prescription section, and you complete the financial and demographic sections. Submit the signed form and proof of income (tax return, pay stubs, or Social Security letter) by fax or mail.

How long does approval take and how is the drug supplied?
Merck typically reviews complete applications within a few business days. Once approved, the drug is shipped directly to your doctor’s office or infusion center for each scheduled treatment cycle. Re-enrollment is required annually or whenever your insurance or income status changes.

What happens if my insurance changes or I lose coverage?
Notify Merck immediately if your insurance status changes. The program can bridge gaps during coverage transitions, but you must reapply if you gain Medicare, Medicaid, or other prescription benefits that cover Keytruda.

Are there state or nonprofit programs that can help?
Some states and independent foundations offer additional cost-sharing assistance for Keytruda. Check with your state health department or organizations such as the Patient Advocate Foundation and CancerCare for co-pay relief or travel grants that may work alongside or instead of the Merck PAP.

When does Keytruda’s patent protection end?
The key U.S. patents for pembrolizumab (Keytruda) expire between 2028 and 2032, with some composition-of-matter and method-of-use patents already listed in the FDA Orange Book. Biosimilar or interchangeable versions are not expected before the primary patents lapse.